Halozyme CEO sells 60,000 shares in Form 4 filing
Halozyme Therapeutics CEO Helen Torley reported selling 60,000 shares between Oct. 6 and Oct. 8 in a Form 4 filing. The filing also shows a same-period exercise of 60,000 shares.
Halozyme Therapeutics CEO Helen Torley reported selling 60,000 shares between Oct. 6 and Oct. 8 in a Form 4 filing. The filing also shows a same-period exercise of 60,000 shares.